CA
NZ
UK
AU
IND
US
…
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Biocardia Inc (NASDAQ: BCDA) are limited; company filings describe it as a development-stage biotechnology firm advancing therapeutic programs. Long-term growth drivers may include successful clinical development and regulatory approvals, strategic partnerships or licensing that enable commercialization, and continued demand for novel treatments; investors may find exposure to upside from program milestones while monitoring execution and financing risk.
The most important risks are substantial clinical and regulatory uncertainty, likely ongoing negative cash flow with a need for additional financing that could dilute shareholders, and competition or intellectual property challenges.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -8.23M | -7.95M | -11.57M | -11.91M | -12.62M |
| Net income | -8.23M | -7.95M | -11.57M | -11.91M | -12.62M |
| Selling general administrative | 3.32M | 3.67M | 4.39M | 4.42M | 5.09M |
| Gross profit | -0.51M | -4.33M | -7.25M | -10.55M | 1.01M |
| Reconciled depreciation | 0.02M | 0.07M | 0.08M | 0.08M | 0.06M |
| Ebit | -8.28M | -8.00M | -11.64M | -11.98M | -12.63M |
| Ebitda | -7.77M | -7.93M | -11.56M | -11.90M | -12.56M |
| Depreciation and amortization | 0.51M | 0.07M | 0.08M | 0.08M | 0.07M |
| Operating income | -8.28M | -8.00M | -11.64M | -11.90M | -12.63M |
| Other operating expenses | 8.28M | 8.06M | 12.12M | 13.25M | 13.64M |
| Interest expense | - | - | - | 0.01M | 0.01M |
| Interest income | - | - | - | - | 0.01M |
| Net interest income | - | - | - | - | 0.01M |
| Income tax expense | - | -7.95M | 0.24M | 0.01M | -0.00M |
| Total revenue | 0.00M | 0.06M | 0.48M | 1.35M | 1.01M |
| Total operating expenses | 7.77M | 3.67M | 4.39M | 13.25M | 13.64M |
| Cost of revenue | 0.51M | 4.39M | 7.73M | 11.90M | 0.00M |
| Total other income expense net | 0.05M | 0.05M | 0.07M | -0.01M | 0.01M |
| Net income from continuing ops | -8.23M | -7.95M | -11.57M | -11.91M | -12.62M |
| Net income applicable to common shares | - | - | - | -11.91M | -12.62M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 3.41M | 3.72M | 2.99M | 9.79M | 15.72M |
| Other current assets | 0.22M | 0.25M | 0.29M | 0.50M | 0.46M |
| Total liab | 2.52M | 2.89M | 4.59M | 4.90M | 5.34M |
| Total stockholder equity | 0.90M | 0.84M | -1.60M | 4.89M | 10.38M |
| Other current liab | 1.35M | 1.02M | 1.82M | 1.62M | 1.44M |
| Common stock | 0.01M | 0.01M | 0.02M | 0.02M | 0.02M |
| Capital stock | 0.01M | 0.01M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -168.35M | -160.12M | -152.18M | -140.60M | -128.70M |
| Other assets | - | - | - | 0.17M | 0.17M |
| Cash | 2.50M | 2.37M | 1.10M | 7.36M | 12.87M |
| Total current liabilities | 2.43M | 2.32M | 3.61M | 3.58M | 3.71M |
| Current deferred revenue | - | 0.53M | 0.56M | 0.96M | 1.53M |
| Net debt | -1.97M | -1.42M | 0.21M | -5.73M | -11.00M |
| Short term debt | 0.44M | 0.39M | 0.33M | 0.32M | 0.24M |
| Short long term debt total | 0.53M | 0.95M | 1.31M | 1.63M | 1.87M |
| Other stockholder equity | 169.23M | 160.95M | 150.55M | 145.48M | 139.06M |
| Property plant equipment | - | - | - | 1.76M | 2.06M |
| Total current assets | 2.73M | 2.62M | 1.46M | 7.86M | 13.48M |
| Net tangible assets | - | - | - | 4.89M | 10.38M |
| Net receivables | 0.02M | 0.00M | 0.06M | 0.20M | 0.15M |
| Inventory | - | - | - | -0.20M | - |
| Accounts payable | 0.64M | 0.39M | 0.89M | 0.68M | 0.51M |
| Non currrent assets other | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M |
| Non current assets total | 0.68M | 1.10M | 1.53M | 1.93M | 2.24M |
| Capital lease obligations | 0.53M | 0.95M | 1.31M | 1.63M | 1.87M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.01M | -0.01M | -0.07M | -0.12M |
| Change to liabilities | - | - | - | -0.50M | -0.07M |
| Total cashflows from investing activities | -0.01M | -0.01M | -0.01M | -0.07M | -0.12M |
| Total cash from financing activities | 7.57M | 9.30M | 3.73M | 5.12M | 1.95M |
| Change to operating activities | - | - | - | 0.34M | -0.07M |
| Net income | -8.23M | -7.95M | -11.57M | -11.91M | -12.62M |
| Change in cash | 0.12M | 1.27M | -6.26M | -5.51M | -8.54M |
| Begin period cash flow | 2.37M | 1.10M | 7.36M | 12.87M | 21.41M |
| End period cash flow | 2.50M | 2.37M | 1.10M | 7.36M | 12.87M |
| Total cash from operating activities | -7.44M | -8.03M | -9.97M | -10.56M | -10.37M |
| Issuance of capital stock | 8.69M | 10.55M | 4.39M | 5.54M | 2.00M |
| Depreciation | 0.02M | 0.07M | 0.08M | 0.08M | 0.06M |
| Change to inventory | - | - | - | - | 0.51M |
| Change to account receivables | -0.02M | 0.10M | 0.12M | -0.05M | 0.09M |
| Other cashflows from financing activities | -0.20M | -1.25M | -0.66M | -0.42M | -0.05M |
| Change to netincome | - | - | - | - | 1.68M |
| Capital expenditures | 0.01M | 0.01M | 0.01M | 0.07M | 0.12M |
| Change in working capital | -0.14M | -1.22M | 0.13M | -0.21M | 0.52M |
| Stock based compensation | 0.43M | 0.74M | 1.03M | 1.18M | 1.66M |
| Other non cash items | 0.48M | 0.33M | 0.35M | 0.29M | 0.02M |
| Free cash flow | -7.44M | -8.03M | -9.99M | -10.63M | -10.48M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BCDA Biocardia Inc |
0.02 2.22% |
0.92 | - | - | 11.35 | 15.28 | 23.81 | -3.16 |
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter A. Altman Ph.D. | CEO, Pres & Director | 1967 |
| Mr. David McClung | Chief Financial Officer | 1963 |
| Mr. Edward M. Gillis | Sr. VP of Devices | 1962 |
| Dr. Ian McNiece Ph.D. | Chief Scientific Officer | 1954 |
| Dr. Sujith Shetty | Chief Medical Officer and VP of Clinical & Regulatory | NA |
| Dr. Peter A. Altman Ph.D. | CEO, President & Director | 1967 |
| Mr. Edward M. Gillis | Senior Vice President of Devices | 1962 |
| Dr. Sujith Shetty MBBS | Chief Medical Officer and VP of Clinical & Regulatory | NA |
| Ms. Miranda Peto Benvenuti | Investor Relations Executive | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...